BRIEF—STA Pharma passes two US FDA inspections

WuXi AppTec subsidiary STA Pharmaceutical has passed two inspections from the US Food and Drug Administration (FDA).

The inspections were passed at the firm’s Analytical Service Unit (ASU) in Shanghai and at its active pharmaceutical ingredient (API) process R&D and manufacturing facility in Changzhou.

VP of quality Mei Hao called the result: “an endorsement of the real time monitoring and quality culture we run across all parts of the company."

“It is also another milestone for our platform, and in our efforts to have geographically integrated capabilities for both drug product and drug substance,” she added.